The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer

Masaki Shiota, Akira Yokomizo, Takumi Adachi, Hirofumi Koga, Akito Yamaguchi, Kenjiro Imada, Ario Takeuchi, Keijiro Kiyoshima, Junichi Inokuchi, Katsunori Tatsugami, Seiji Naito

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To clarify the risk factors and develop a refined risk-stratification model to help in the appropriate selection of docetaxel chemotherapy in patients with castration-resistant prostate cancer. Methods: This study included 97 Japanese patients with castration-resistant prostate cancer who were treated with 70-75 mg/m2 docetaxel and 10 mg prednisone every 3 or 4 weeks from 2008 to 2013. The oncological outcomes and prognostic significance of clinicopathological factors were analyzed, and significant prognostic factors were used to develop a risk-stratification model. Results: Prostate-specific antigen decline was observed in 75 patients (77.3%), including 43 (44.3%) who achieved a prostate-specific antigen decline of ≥50%. The median progressionfree survival and overall survival were 5.1 and 20.8 months, respectively. Univariate analysis identified performance status, alkaline phosphatase value, visceral metastasis, duration from diagnosis, duration from initiation of hormone treatment and prior treatment with estramustine as significant predictors of overall survival. Among these, alkaline phosphatase value, visceral metastasis and duration from initiation of hormone treatment were independent prognostic factors in multivariate analysis. Furthermore, risk classification according to the number of independent risk factors present effectively stratified survival among docetaxel-treated castrationresistant prostate cancer patients. Conclusions: Oncologic outcomes in Japanese patients with castration-resistant prostate cancer receiving docetaxel chemotherapy were comparable to or slightly better than those in Western populations, and the risk-stratification model developed in this study may help to predict prognosis and contribute to the selection of suitable therapy after castration resistance.

Original languageEnglish
Pages (from-to)860-867
Number of pages8
JournalJapanese journal of clinical oncology
Volume44
Issue number9
DOIs
Publication statusPublished - Sep 2014

Fingerprint

docetaxel
Castration
Prostatic Neoplasms
Drug Therapy
Survival
Prostate-Specific Antigen
Alkaline Phosphatase
Estramustine
Hormones
Neoplasm Metastasis
Therapeutics
Prednisone
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer. / Shiota, Masaki; Yokomizo, Akira; Adachi, Takumi; Koga, Hirofumi; Yamaguchi, Akito; Imada, Kenjiro; Takeuchi, Ario; Kiyoshima, Keijiro; Inokuchi, Junichi; Tatsugami, Katsunori; Naito, Seiji.

In: Japanese journal of clinical oncology, Vol. 44, No. 9, 09.2014, p. 860-867.

Research output: Contribution to journalArticle

@article{6ce66e4cb9234398bf9e67a1939cb1f2,
title = "The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer",
abstract = "Objective: To clarify the risk factors and develop a refined risk-stratification model to help in the appropriate selection of docetaxel chemotherapy in patients with castration-resistant prostate cancer. Methods: This study included 97 Japanese patients with castration-resistant prostate cancer who were treated with 70-75 mg/m2 docetaxel and 10 mg prednisone every 3 or 4 weeks from 2008 to 2013. The oncological outcomes and prognostic significance of clinicopathological factors were analyzed, and significant prognostic factors were used to develop a risk-stratification model. Results: Prostate-specific antigen decline was observed in 75 patients (77.3{\%}), including 43 (44.3{\%}) who achieved a prostate-specific antigen decline of ≥50{\%}. The median progressionfree survival and overall survival were 5.1 and 20.8 months, respectively. Univariate analysis identified performance status, alkaline phosphatase value, visceral metastasis, duration from diagnosis, duration from initiation of hormone treatment and prior treatment with estramustine as significant predictors of overall survival. Among these, alkaline phosphatase value, visceral metastasis and duration from initiation of hormone treatment were independent prognostic factors in multivariate analysis. Furthermore, risk classification according to the number of independent risk factors present effectively stratified survival among docetaxel-treated castrationresistant prostate cancer patients. Conclusions: Oncologic outcomes in Japanese patients with castration-resistant prostate cancer receiving docetaxel chemotherapy were comparable to or slightly better than those in Western populations, and the risk-stratification model developed in this study may help to predict prognosis and contribute to the selection of suitable therapy after castration resistance.",
author = "Masaki Shiota and Akira Yokomizo and Takumi Adachi and Hirofumi Koga and Akito Yamaguchi and Kenjiro Imada and Ario Takeuchi and Keijiro Kiyoshima and Junichi Inokuchi and Katsunori Tatsugami and Seiji Naito",
year = "2014",
month = "9",
doi = "10.1093/jjco/hyu081",
language = "English",
volume = "44",
pages = "860--867",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer

AU - Shiota, Masaki

AU - Yokomizo, Akira

AU - Adachi, Takumi

AU - Koga, Hirofumi

AU - Yamaguchi, Akito

AU - Imada, Kenjiro

AU - Takeuchi, Ario

AU - Kiyoshima, Keijiro

AU - Inokuchi, Junichi

AU - Tatsugami, Katsunori

AU - Naito, Seiji

PY - 2014/9

Y1 - 2014/9

N2 - Objective: To clarify the risk factors and develop a refined risk-stratification model to help in the appropriate selection of docetaxel chemotherapy in patients with castration-resistant prostate cancer. Methods: This study included 97 Japanese patients with castration-resistant prostate cancer who were treated with 70-75 mg/m2 docetaxel and 10 mg prednisone every 3 or 4 weeks from 2008 to 2013. The oncological outcomes and prognostic significance of clinicopathological factors were analyzed, and significant prognostic factors were used to develop a risk-stratification model. Results: Prostate-specific antigen decline was observed in 75 patients (77.3%), including 43 (44.3%) who achieved a prostate-specific antigen decline of ≥50%. The median progressionfree survival and overall survival were 5.1 and 20.8 months, respectively. Univariate analysis identified performance status, alkaline phosphatase value, visceral metastasis, duration from diagnosis, duration from initiation of hormone treatment and prior treatment with estramustine as significant predictors of overall survival. Among these, alkaline phosphatase value, visceral metastasis and duration from initiation of hormone treatment were independent prognostic factors in multivariate analysis. Furthermore, risk classification according to the number of independent risk factors present effectively stratified survival among docetaxel-treated castrationresistant prostate cancer patients. Conclusions: Oncologic outcomes in Japanese patients with castration-resistant prostate cancer receiving docetaxel chemotherapy were comparable to or slightly better than those in Western populations, and the risk-stratification model developed in this study may help to predict prognosis and contribute to the selection of suitable therapy after castration resistance.

AB - Objective: To clarify the risk factors and develop a refined risk-stratification model to help in the appropriate selection of docetaxel chemotherapy in patients with castration-resistant prostate cancer. Methods: This study included 97 Japanese patients with castration-resistant prostate cancer who were treated with 70-75 mg/m2 docetaxel and 10 mg prednisone every 3 or 4 weeks from 2008 to 2013. The oncological outcomes and prognostic significance of clinicopathological factors were analyzed, and significant prognostic factors were used to develop a risk-stratification model. Results: Prostate-specific antigen decline was observed in 75 patients (77.3%), including 43 (44.3%) who achieved a prostate-specific antigen decline of ≥50%. The median progressionfree survival and overall survival were 5.1 and 20.8 months, respectively. Univariate analysis identified performance status, alkaline phosphatase value, visceral metastasis, duration from diagnosis, duration from initiation of hormone treatment and prior treatment with estramustine as significant predictors of overall survival. Among these, alkaline phosphatase value, visceral metastasis and duration from initiation of hormone treatment were independent prognostic factors in multivariate analysis. Furthermore, risk classification according to the number of independent risk factors present effectively stratified survival among docetaxel-treated castrationresistant prostate cancer patients. Conclusions: Oncologic outcomes in Japanese patients with castration-resistant prostate cancer receiving docetaxel chemotherapy were comparable to or slightly better than those in Western populations, and the risk-stratification model developed in this study may help to predict prognosis and contribute to the selection of suitable therapy after castration resistance.

UR - http://www.scopus.com/inward/record.url?scp=84906879061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906879061&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyu081

DO - 10.1093/jjco/hyu081

M3 - Article

C2 - 24951829

AN - SCOPUS:84906879061

VL - 44

SP - 860

EP - 867

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 9

ER -